These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21944793)

  • 1. Is primary endocrine therapy effective in treating the elderly, unfit patient with breast cancer?
    Osborn G; Jones M; Champ C; Gower-Thomas K; Vaughan-Williams E
    Ann R Coll Surg Engl; 2011 May; 93(4):286-9. PubMed ID: 21944793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour grade on core biopsy and evidence of axillary involvement on ultrasound predicts response in elderly co-morbid patients treated with primary hormone therapy for oestrogen receptor positive breast carcinoma.
    Layfield DM; Mohamud M; Odofin O; Walsh C; Royle GT; Cutress RI
    Surgeon; 2015 Apr; 13(2):61-8. PubMed ID: 24411703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer.
    Wink CJ; Woensdregt K; Nieuwenhuijzen GA; van der Sangen MJ; Hutschemaekers S; Roukema JA; Tjan-Heijnen VC; Voogd AC
    Ann Surg Oncol; 2012 Apr; 19(4):1185-91. PubMed ID: 22031063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
    Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological profile of oestrogen receptor positive primary breast cancers in the elderly and response to primary endocrine therapy.
    Okunade G; Green AR; Ying M; Agrawal A; Paish EC; Aleskandrany M; Winterbottom L; Hassell K; Morgan DA; Ellis IO; Cheung KL
    Crit Rev Oncol Hematol; 2009 Oct; 72(1):76-82. PubMed ID: 19515574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary Hormonal Therapy for Elderly Breast Cancer Patients: Single Institution Experience.
    Panal M; Sánchez-Mendez JI; Revello R; Abehsera D; de Santiago J; Zapardiel I
    Gynecol Obstet Invest; 2015; 80(1):10-4. PubMed ID: 25401708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE
    Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
    Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
    Semiglazov VF; Semiglazov VV; Dashyan GA; Ziltsova EK; Ivanov VG; Bozhok AA; Melnikova OA; Paltuev RM; Kletzel A; Berstein LM
    Cancer; 2007 Jul; 110(2):244-54. PubMed ID: 17538978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
    Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
    Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
    Jakesz R; Greil R; Gnant M; Schmid M; Kwasny W; Kubista E; Mlineritsch B; Tausch C; Stierer M; Hofbauer F; Renner K; Dadak C; Rücklinger E; Samonigg H;
    J Natl Cancer Inst; 2007 Dec; 99(24):1845-53. PubMed ID: 18073378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience of hormonal therapy with anastrozole for previously treated metastatic breast cancer.
    Lavrenkov K; Man S; Geffen DB; Cohen Y
    Isr Med Assoc J; 2002 Mar; 4(3):176-7. PubMed ID: 11908256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.
    Gil JM; Rubio-Terrés C; Del Castillo A; González P; Canorea F
    Clin Transl Oncol; 2006 May; 8(5):339-48. PubMed ID: 16760009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
    Carlson RW; Henderson IC
    Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole.
    Rose C; Vtoraya O; Pluzanska A; Davidson N; Gershanovich M; Thomas R; Johnson S; Caicedo JJ; Gervasio H; Manikhas G; Ben Ayed F; Burdette-Radoux S; Chaudri-Ross HA; Lang R
    Eur J Cancer; 2003 Nov; 39(16):2318-27. PubMed ID: 14556923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial.
    Thürlimann B; Hess D; Köberle D; Senn I; Ballabeni P; Pagani O; Perey L; Aebi S; Rochlitz C; Goldhirsch A
    Breast Cancer Res Treat; 2004 Jun; 85(3):247-54. PubMed ID: 15111763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing the risk of late recurrence in hormone-responsive breast cancer.
    Cufer T
    Ann Oncol; 2007 Sep; 18 Suppl 8():viii18-25. PubMed ID: 17890210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial.
    Kurosumi M; Takatsuka Y; Watanabe T; Imoto S; Inaji H; Tsuda H; Akiyama F; Sakamoto G; Ikeda T; Noguchi S
    J Cancer Res Clin Oncol; 2008 Jun; 134(6):715-22. PubMed ID: 18075758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
    N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.